Plus Therapeutics, Inc. (PSTV)

Market Cap	3.60M
Revenue (ttm)	2.58M
Net Income (ttm)	-17.16M
Shares Out	2.88M
EPS (ttm)	-7.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,871
Open	1.25
Previous Close	1.24
Day's Range	1.21 - 1.25
52-Week Range	1.18 - 10.95
Beta	0.34
Analysts	Strong Buy
Price Target	31.67 (+2,433.6%)
Earnings Date	Oct 19, 2023

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: PSTV

Analyst Forecast

According to 3 analysts, the average rating for PSTV stock is "Strong Buy." The 12-month stock price forecast is $31.67, which is an increase of 2,433.60% from the latest price.

Price Target

$31.67

(2,433.60% upside)

Analyst Consensus: Strong Buy